Florian Sauer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florian Sauer has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Kisker
University of Würzburg
4 shared publications - Christoph Sotriffer
Institute of Pharmacy and Food Chemistry, Julius-Maximilians-Universität Würzburg
3 shared publications - Alexander V. Statsyuk
Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy
2 shared publications - Christian Tiesmeyer
Rudolf Virchow Center for Experimental Biomedicine Institute of Structural Biology University of Würzburg Josef-Schneider-Straße 2 97080 Würzburg Germany
2 shared publications - Eva Altmann
Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
2 shared publications - Stefan G. Kathman
Department of Chemistry, The Scripps Research Institute, La Jolla, USA
2 shared publications
Latest Publications
- Open Access
- 30 May 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (7) , 2950-2973
Structural basis for the bi-specificity of USP25 and USP28 inhibitors
The development of cancer therapeutics is often hindered by the fact that specific oncogenes cannot be directly pharmaceutically addressed. Targeting deubiquitylases that stabilize these oncogenes provides a promising alternative. USP28 and USP25 have been identified as such target deubiquitylases, and several small-molecule inhibitors indiscriminately inhibiting both enzymes have been developed. To obtain insights into their mode of inhibition, we structurally and functionally characterized USP28 in the presence of the three different inhibitors AZ1, Vismodegib and FT206. The compounds bind into a common pocket acting as a molecular sink. Our analysis provides an explanation why the two enzymes are inhibited with similar potency while other deubiquitylases are not affected. Furthermore, a key glutamate residue at position 366/373 in USP28/USP25 plays a central structural role for pocket stability and thereby for inhibition and activity. Obstructing the inhibitor-binding pocket by mutation of this glutamate may provide a tool to accelerate future drug development efforts for selective inhibitors of either USP28 or USP25 targeting distinct binding pockets.
- 30 May 2024
- Published by Springer Nature in EMBO Reports
- Vol. 25 (7) , 2950-2973
Open AccessStructural basis for the bi-specificity of USP25 and USP28 inhibitors
The development of cancer therapeutics is often hindered by the fact that specific oncogenes cannot be directly pharmaceutically addressed. Targeting deubiquitylases that stabilize these oncogenes provides a promising alternative. USP28 and USP25 have been identified as such target deubiquitylases, and several small-molecule inhibitors indiscriminately inhibiting both enzymes have been developed. To obtain insights into their mode of inhibition, we structurally and functionally characterized USP28 in the presence of the three different inhibitors AZ1, Vismodegib and FT206. The compounds bind into a common pocket acting as a molecular sink. Our analysis provides an explanation why the two enzymes are inhibited with similar potency while other deubiquitylases are not affected. Furthermore, a key glutamate residue at position 366/373 in USP28/USP25 plays a central structural role for pocket stability and thereby for inhibition and activity. Obstructing the inhibitor-binding pocket by mutation of this glutamate may provide a tool to accelerate future drug development efforts for selective inhibitors of either USP28 or USP25 targeting distinct binding pockets.
- Open Access
- 28 May 2024
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 31 (10) , 1580-1588
XPD stalled on cross-linked DNA provides insight into damage verification
The superfamily 2 helicase XPD is a central component of the general transcription factor II H (TFIIH), which is essential for transcription and nucleotide excision DNA repair (NER). Within these two processes, the helicase function of XPD is vital for NER but not for transcription initiation, where XPD acts only as a scaffold for other factors. Using cryo-EM, we deciphered one of the most enigmatic steps in XPD helicase action: the active separation of double-stranded DNA (dsDNA) and its stalling upon approaching a DNA interstrand cross-link, a highly toxic form of DNA damage. The structure shows how dsDNA is separated and reveals a highly unusual involvement of the Arch domain in active dsDNA separation. Combined with mutagenesis and biochemical analyses, we identified distinct functional regions important for helicase activity. Surprisingly, those areas also affect core TFIIH translocase activity, revealing a yet unencountered function of XPD within the TFIIH scaffold. In summary, our data provide a universal basis for NER bubble formation, XPD damage verification and XPG incision.
- 28 May 2024
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 31 (10) , 1580-1588
Open AccessXPD stalled on cross-linked DNA provides insight into damage verification
The superfamily 2 helicase XPD is a central component of the general transcription factor II H (TFIIH), which is essential for transcription and nucleotide excision DNA repair (NER). Within these two processes, the helicase function of XPD is vital for NER but not for transcription initiation, where XPD acts only as a scaffold for other factors. Using cryo-EM, we deciphered one of the most enigmatic steps in XPD helicase action: the active separation of double-stranded DNA (dsDNA) and its stalling upon approaching a DNA interstrand cross-link, a highly toxic form of DNA damage. The structure shows how dsDNA is separated and reveals a highly unusual involvement of the Arch domain in active dsDNA separation. Combined with mutagenesis and biochemical analyses, we identified distinct functional regions important for helicase activity. Surprisingly, those areas also affect core TFIIH translocase activity, revealing a yet unencountered function of XPD within the TFIIH scaffold. In summary, our data provide a universal basis for NER bubble formation, XPD damage verification and XPG incision.
- Open Access
- 13 March 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Single molecule analysis reveals monomeric XPA bends DNA and undergoes episodic linear diffusion during damage search
Nucleotide excision repair (NER) removes a wide range of DNA lesions, including UV-induced photoproducts and bulky base adducts. XPA is an essential protein in eukaryotic NER, although reports about its stoichiometry and role in damage recognition are controversial. Here, by PeakForce Tapping atomic force microscopy, we show that human XPA binds and bends DNA by ∼60° as a monomer. Furthermore, we observe XPA specificity for the helix-distorting base adduct N-(2’-deoxyguanosin-8-yl)-2-acetylaminofluorene over non-damaged dsDNA. Moreover, single molecule fluorescence microscopy reveals that DNA-bound XPA exhibits multiple modes of linear diffusion between paused phases. The presence of DNA damage increases the frequency of pausing. Truncated XPA, lacking the intrinsically disordered N- and C-termini, loses specificity for DNA lesions and shows less pausing on damaged DNA. Our data are consistent with a working model in which monomeric XPA bends DNA, displays episodic phases of linear diffusion along DNA, and pauses in response to DNA damage.
- 13 March 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-14
Open AccessSingle molecule analysis reveals monomeric XPA bends DNA and undergoes episodic linear diffusion during damage search
Nucleotide excision repair (NER) removes a wide range of DNA lesions, including UV-induced photoproducts and bulky base adducts. XPA is an essential protein in eukaryotic NER, although reports about its stoichiometry and role in damage recognition are controversial. Here, by PeakForce Tapping atomic force microscopy, we show that human XPA binds and bends DNA by ∼60° as a monomer. Furthermore, we observe XPA specificity for the helix-distorting base adduct N-(2’-deoxyguanosin-8-yl)-2-acetylaminofluorene over non-damaged dsDNA. Moreover, single molecule fluorescence microscopy reveals that DNA-bound XPA exhibits multiple modes of linear diffusion between paused phases. The presence of DNA damage increases the frequency of pausing. Truncated XPA, lacking the intrinsically disordered N- and C-termini, loses specificity for DNA lesions and shows less pausing on damaged DNA. Our data are consistent with a working model in which monomeric XPA bends DNA, displays episodic phases of linear diffusion along DNA, and pauses in response to DNA damage.
- Open Access
- 8 October 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2012
Front Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)
- 8 October 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2012
Open AccessFront Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)
- 6 September 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2014-2023
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.
- 6 September 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2014-2023
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.